About us

Dirk Witters

Chairman of the Board

Chairman of the Board | Committee Chairman: Compensation, Nomination and Governance | Committee Served: Audit

Since 2019 Dirk Witters is an independent advisor and executive partner in a family office structure, where he advises on capital raising assignments (cumulative volume of EUR 250 million raised through the family office network) and direct investments in industries including healthcare and real estate development. In this capacity Dirk serves as director in an early-stage business in orthopedic implants and in an HR-services provider.

From mid 2020 to April 2022, Dirk was President of the Board of Biostrand BV (discontinued when the company was acquired by IPA).

Previously Mr. Witters served as executive partner in a corporate finance boutique and was advisor to the founder of New Rhein Healthcare Investors, a private equity investment firm focused on healthcare therapeutics and medical devices, where he assisted with the capital raise of the second investment fund.

Mr. Witters also spent 20+ years with KBC Group’s Corporate and Investment Banking division where he gained experience in business development, strategy execution, advisory and corporate finance.

Dr. Jennifer Bath

Director

Director

Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global client relations and high value target teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Jon Lieber

Director

Director | Committee Chairman: Audit | Committee served: Compensation, Nomination and Governance

Jon is currently the Chief Financial Officer of Rallybio. He has more than 30 years of experience as a CFO for public and private life sciences companies and an investment banker. He has significant experience in strategic planning, capital raising (including IPO preparation and execution), investor relations, and mergers and acquisitions for both pre- and post-revenue companies. Prior to Rallybio, he served as the CFO of Applied Genetic Technologies Corporation (AGTC), a publicly traded biotechnology gene therapy company focused on rare diseases, where he led all capital raising activities and was responsible for accounting and finance, human resources, investor relations, information technology and project management.

Prior to AGTC, Jon was a Managing Director at Danforth Advisors, a private equity-backed firm, where he provided CFO services and strategic advice to public and private healthcare companies. Previously, he has served as CFO at firms including Histogenics, a publicly traded cell therapy company, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Jon began his career in healthcare as an investment banker at Salomon Brothers / Salomon Smith Barney and SG Cowen.

Jon is also a member of the Board of Directors of Salarius Pharmaceuticals and serves on the Audit and Nominating and Governance Committees.